Cargando…

Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors

This study investigates the effects of a site-directed TG2-selective inhibitor on the lung myofibroblast phenotype and ECM deposition to elucidate TG2 as a novel therapeutic target in idiopathic pulmonary fibrosis (IPF)—an incurable progressive fibrotic disease. IPF fibroblasts showed increased expr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fell, Shaun, Wang, Zhuo, Blanchard, Andy, Nanthakumar, Carmel, Griffin, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910249/ https://www.ncbi.nlm.nih.gov/pubmed/33474654 http://dx.doi.org/10.1007/s00726-020-02938-w

Ejemplares similares

Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor
por: Wang, Zhuo, et al.
Publicado: (2018)

Small Molecule Inhibitors Target the Tissue Transglutaminase and Fibronectin Interaction
por: Yakubov, Bakhtiyor, et al.
Publicado: (2014)

Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis
por: John, Alison E., et al.
Publicado: (2020)

Searching for Novel Candidate Small Molecules for Ameliorating Idiopathic Pulmonary Fibrosis: a Narrative Review
por: Kim, Kyung-il, et al.
Publicado: (2023)

Update on therapeutic management of idiopathic pulmonary fibrosis
por: Tzouvelekis, Argyris, et al.
Publicado: (2015)

Small airway dysfunction in idiopathic pulmonary fibrosis
por: Yin, Chengsheng, et al.
Publicado: (2022)

Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort
por: Organ, Louise A., et al.
Publicado: (2019)

Hospitalizations in patients with idiopathic pulmonary fibrosis
por: Kim, Hyun J., et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
por: Spagnolo, Paolo, et al.
Publicado: (2012)

Extracellular vesicles in idiopathic pulmonary fibrosis: pathogenesis and therapeutics
por: Fujita, Yu
Publicado: (2022)

Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
por: Chen, I-Chen, et al.
Publicado: (2022)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada
por: Tarride, Jean-Eric, et al.
Publicado: (2018)

A Novel Therapeutic Target in Inflammatory Uveitis: Transglutaminase 2 Inhibitor
por: Sohn, Joonhong, et al.
Publicado: (2010)

Transglutaminase-2: Nature’s Glue in Lung Fibrosis?
por: Sanders, Yan Y., et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics
por: Costabel, U, et al.
Publicado: (2013)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Idiopathic and immune‐related pulmonary fibrosis: diagnostic and therapeutic challenges
por: McLean‐Tooke, Andrew, et al.
Publicado: (2019)

Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis
por: Yang, Shengnan, et al.
Publicado: (2021)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Small airway dysfunction in Chinese patients with idiopathic pulmonary fibrosis
por: Zhang, Xinran, et al.
Publicado: (2022)

Biochemical and Functional Characterization of the Three Zebrafish Transglutaminases 2
por: Lisetto, Manuel, et al.
Publicado: (2023)

Content Analysis of Idiopathic Pulmonary Fibrosis-related Information on Twitter
por: Ong, Shaun, et al.
Publicado: (2022)

Role of Transglutaminase 2 in Cell Death, Survival, and Fibrosis
por: Tatsukawa, Hideki, et al.
Publicado: (2021)

A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells
por: Katt, William P., et al.
Publicado: (2018)

Lung function trajectories in patients with idiopathic pulmonary fibrosis
por: Neely, Megan L, et al.
Publicado: (2023)

Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
por: Kim, Suji, et al.
Publicado: (2020)

Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis
por: Wang, Yunguan, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions
por: Mattoo, Hamid, et al.
Publicado: (2021)

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
por: Estornut, Cristina, et al.
Publicado: (2022)

CC Chemokines in Idiopathic Pulmonary Fibrosis: Pathogenic Role and Therapeutic Potential
por: Liu, Shanshan, et al.
Publicado: (2023)

Soluble intercellular adhesion molecule-1 for stable and acute phases of idiopathic pulmonary fibrosis
por: Okuda, Ryo, et al.
Publicado: (2015)

Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis
por: Wang, Rui, et al.
Publicado: (2022)

Smoking and Idiopathic Pulmonary Fibrosis
por: Oh, Chad K., et al.
Publicado: (2012)

Autophagy in Idiopathic Pulmonary Fibrosis
por: Patel, Avignat S., et al.
Publicado: (2012)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Epidemiology of idiopathic pulmonary fibrosis
por: Ley, Brett, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_usm2gbf7fc4q60tb8t4ojaaoph